These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 37434085)

  • 1. Management of Type 2 Diabetes in Frail Older Adults.
    Bahat G; Ozkok S; Petrovic M
    Drugs Aging; 2023 Sep; 40(9):751-761. PubMed ID: 37434085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoglycaemic therapy in frail older people with type 2 diabetes mellitus-a choice determined by metabolic phenotype.
    Sinclair AJ; Pennells D; Abdelhafiz AH
    Aging Clin Exp Res; 2022 Sep; 34(9):1949-1967. PubMed ID: 35723859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of type 2 diabetes mellitus in older adults: eight case studies with focus SGLT-2 inhibitors and metformin.
    Bahat G; Catikkas NM; Karan MA; Petrovic M
    Acta Clin Belg; 2022 Aug; 77(4):727-734. PubMed ID: 34251983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular risk reduction in older people with type 2 diabetes mellitus-a comprehensive narrative review.
    Si PEH; Parker S; Abdelhafiz D; Summerbell A; Muzulu S; Abdelhafiz AH
    Diabetes Res Clin Pract; 2024 May; 211():111662. PubMed ID: 38599285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Newer anti-diabetic therapies with low hypoglycemic risk-potential advantages for frail older people.
    Emmerton D; Abdelhafiz A
    Hosp Pract (1995); 2021 Aug; 49(3):164-175. PubMed ID: 33729898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New hypoglycaemic therapy in frail older people with diabetes mellitus-phenotypic status likely to be more important than functional status.
    Abdelhafiz AH; Emmerton D; Sinclair AJ
    Diabetes Res Clin Pract; 2020 Nov; 169():108438. PubMed ID: 32920102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The outcome of frailty in older people with diabetes as a function of glycaemic control and hypoglycaemic therapy: a review.
    Keegan GL; Bhardwaj N; Abdelhafiz AH
    Expert Rev Endocrinol Metab; 2023; 18(5):361-375. PubMed ID: 37489773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes.
    Zhuo M; Hawley CE; Paik JM; Bessette LG; Wexler DJ; Kim DH; Tong AY; Kim SC; Patorno E
    JAMA Netw Open; 2021 Oct; 4(10):e2130762. PubMed ID: 34705014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
    Li CX; Liang S; Gao L; Liu H
    PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
    Ikonomidis I; Pavlidis G; Thymis J; Birba D; Kalogeris A; Kousathana F; Kountouri A; Balampanis K; Parissis J; Andreadou I; Katogiannis K; Dimitriadis G; Bamias A; Iliodromitis E; Lambadiari V
    J Am Heart Assoc; 2020 May; 9(9):e015716. PubMed ID: 32326806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study.
    Lugner M; Sattar N; Miftaraj M; Ekelund J; Franzén S; Svensson AM; Eliasson B
    Cardiovasc Diabetol; 2021 Mar; 20(1):67. PubMed ID: 33752680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM).
    Gourdy P; Darmon P; Dievart F; Halimi JM; Guerci B
    Cardiovasc Diabetol; 2023 Apr; 22(1):79. PubMed ID: 37005640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frailty and safety: the example of diabetes.
    Abbatecola AM; Olivieri F; Corsonello A; Strollo F; Fumagalli A; Lattanzio F
    Drug Saf; 2012 Jan; 35 Suppl 1():63-71. PubMed ID: 23446787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study.
    Sohn M; Dietrich JW; Nauck MA; Lim S
    Cardiovasc Diabetol; 2023 Jun; 22(1):153. PubMed ID: 37381019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of SGLT-2i in overweight/obese, non-diabetic individuals: a meta-analysis of randomized controlled trials.
    Shi Y; Si Y; Fu R; Zhang M; Jiang K; Dai W; Shen J; Li X; Yuan Y
    Endokrynol Pol; 2022; 73(1):71-80. PubMed ID: 35119088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes.
    Lajara R
    Postgrad Med; 2019 Nov; 131(8):555-565. PubMed ID: 31580737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA.
    Shin H; Schneeweiss S; Glynn RJ; Patorno E
    Diabetes Care; 2021 Aug; 44(8):1774-1782. PubMed ID: 34385345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study.
    Paul SK; Bhatt DL; Montvida O
    Eur Heart J; 2021 May; 42(18):1728-1738. PubMed ID: 33289789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints.
    Patoulias D; Katsimardou A; Kalogirou MS; Zografou I; Toumpourleka M; Imprialos K; Stavropoulos K; Stergiou I; Papadopoulos C; Doumas M
    Diabetes Metab; 2020 Sep; 46(4):272-279. PubMed ID: 32437914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.